KLK3 and prostate carcinoma: In a study by Trock et al. with median pre-RT PSA < 1.0 ng/ml, salvage RT performed within 2 years after biochemical recurrence significantly improved prostate cancer-specific survival among patients with PSADT of less than 6 months (HR: 0.14) [5].